Allergan PLC (AGN)

• Annual Data
• Quarterly Data

Allergan PLC, common-size consolidated income statement

	12 months ended	Dec 31, 2018		Dec 31, 2017		Dec 31, 2016		Dec 31, 2015		Dec 31, 2014
	Net revenues
	Cost of sales, excludes amortization and impairment of acquired intangibles including product rights
	Gross profit
	Research and development
	Selling and marketing
	General and administrative
	Amortization
	Goodwill impairments
	In-process research and development impairments
	Loss on assets held for sale
	Asset sales and impairments, net
	Operating loss
	Interest income
	Interest expense
	Teva Share Activity
	Sale of businesses
	Debt extinguishment costs as part of the debt tender offer
	Debt extinguishment other
	Other-than-temporary impairments
	Dividend income
	Naurex recovery
	Forward sale of Teva shares
	Pfizer termination fee, Allergan plc only
	Bridge loan commitment fee
	Interest rate lock
	Loss on sale of assets
	Other
	Other income (expense), net
	Loss before income taxes and noncontrolling interest
	Benefit for income taxes
	Net loss from continuing operations, net of tax
	Income (loss) from discontinued operations, net of tax
	Net income (loss)
	Income attributable to noncontrolling interest
	Net income (loss) attributable to shareholders
	Dividends on preferred shares
	Net income (loss) attributable to ordinary shareholders

Based on: 10-K (filing date: 2019-02-15), 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-24), 10-K (filing date: 2016-02-26), 10-K (filing date: 2015-02-18).